title: The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
abstract: OBJECTIVE
  To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
  
  
  METHODS
  Post hoc analysis of over 2,000 metabolic syndrome patients administered either FA + low- or moderate-dose statin; FA alone; or low-, moderate-, or high-dose statin alone.
  
  
  RESULTS
  FA + low- or moderate-dose statin combination therapy reduced the presence of metabolic syndrome (35.7 or 35.9%, respectively) more than low-, moderate-, or high-dose statin monotherapy (15.5, 16.6, or 13.8%, respectively), mostly due to improvements in triglycerides and HDL cholesterol levels. Mean glucose levels slightly decreased with FA monotherapy, slightly increased with statin monotherapy, and were essentially unchanged with FA + statin. FA with or without statin also reduced non-HDL cholesterol, apolipoprotein B, total cholesterol, VLDL cholesterol, and high-sensitivity C-reactive protein.
  
  
  CONCLUSIONS
  FA + statin in patients with mixed dyslipidemia reduces the prevalence of metabolic syndrome.
authors.affiliation: Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA. hbaysmd@aol.com
authors.forename: Harold E
authors.initials: HE
authors.lastname: Bays
authors.forename: Eli M
authors.initials: EM
authors.lastname: Roth
authors.forename: James M
authors.initials: JM
authors.lastname: McKenney
authors.forename: Maureen T
authors.initials: MT
authors.lastname: Kelly
authors.forename: Kamlesh M
authors.initials: KM
authors.lastname: Thakker
authors.forename: Carolyn M
authors.initials: CM
authors.lastname: Setze
authors.forename: Katie
authors.initials: K
authors.lastname: Obermeyer
authors.forename: Darryl J
authors.initials: DJ
authors.lastname: Sleep
mesh_terms: D050171:Dyslipidemias / Q000188:drug therapy* / Q000453:epidemiology; D011345:Fenofibrate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000453:epidemiology; D019821:Simvastatin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000960:Hypolipidemic Agents; D019821:Simvastatin; C006012:fenofibric acid; D011345:Fenofibrate